Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2010

View Archived Issues

Clinical data support potential of rufinamide for neuropathic pain

Cypher sirolimus-eluting stent superior to Endeavor zotarolimus-eluting stent in phase III trial

BT-061 improves psoriasis in double-blind trial

New fatty-acid amide hydrolase 1 inhibitor JNJ-40355003 has preclinical analgesic effects

Boehringer Ingelheim claims new bradykinin B1 receptor antagonists

FDA grants orphan drug status for BDM-E in retinitis pigmentosa

GSK presents new prostanoid DP1 receptor antagonists

NicOx and Merck & Co. expand license agreement for new NO donors

Mimetica describes new melanocortin MC1 receptor agonists

Galderma claims new inhibitors of ACAT-1

Micrus Endovascular stockholders approve merger with Johnson & Johnson

Respiratorius describes new bronchorelaxants

FDA approves Savient Pharmaceuticals' pegloticase for gout

Eisai claims new inhibitors of beta-amyloid peptide production

Synta Pharma expands phase II STA-9090 trial in NSCLC

BioCryst presents data from forodesine oncology studies

GTx-758 induces medical castration in phase II trial

Neurocrine reports data on GSK-561679 in major depressive disorder

Mochida Pharmaceutical files NDA in Japan for escitalopram

FDA grants fast track status for ARC-4558 in diabetes-associated pain

Pepscan Therapeutics and Tibotec form research collaboration

NexMed changes name to Apricus Biosciences

FDA extends review date for AstraZeneca's Brilinta NDA in ACS

FDA accepts Sanofi Pasteur's sBLA for Fluzone vaccine

BTG initiates first of three phase III studies of Varisolve in U.S.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...